Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ALGS
ALGS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALGS News
Aligos Therapeutics Secures $25M License Deal with Amoytop for HBV Therapy
1d ago
NASDAQ.COM
Aligos Signs Exclusive Licensing Deal with Xiamen Amoytop
1d ago
stocktwits
Aligos Therapeutics Reports Positive Data on Pevifoscorvir Sodium
May 27 2026
NASDAQ.COM
Aligos Announces Ten Abstracts Accepted at EASL Congress 2026
May 13 2026
Newsfilter
Aligos Therapeutics Q1 Earnings Beat Expectations
May 07 2026
seekingalpha
Aligos Therapeutics Grants Stock Options to New Employees
Apr 24 2026
NASDAQ.COM
Aligos Grants 10,700 Stock Options to New Employees
Apr 24 2026
Newsfilter
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
Apr 16 2026
stocktwits
Aligos Enters Exclusive Licensing Agreement with Xiamen Amoytop Biotech
Apr 16 2026
seekingalpha
Aligos Enters Exclusive License Agreement with Amoytop
Apr 16 2026
Newsfilter
Aligos Therapeutics Reports Positive Interim Results in HBV Study
Apr 15 2026
NASDAQ.COM
Aligos Receives FDA Fast Track Designation for Pevifoscorvir Sodium
Apr 14 2026
Newsfilter
Aligos Therapeutics Reports 2025 Financial Progress and Pipeline Advancements
Mar 06 2026
NASDAQ.COM
Aligos Therapeutics Q4 Earnings Beat Expectations
Mar 05 2026
seekingalpha
Onco3R Appoints Lawrence Blatt as Board Chair to Drive Growth
Jan 08 2026
Globenewswire
Aligos Grants 14,100 Stock Options to New Employees Under Inducement Plan
Dec 12 2025
Globenewswire
Show More News
